All Infection Prevention & Control articles – Page 10
-
NewsNovel app tracks travel-related illnesses
Travelers fall ill surprisingly often during their travels, with health issues occurring on more than one-third of trips, reveals data collected by a novel travel app developed by researchers in cooperation with the World Health Organization (WHO).
-
NewsHalf of all patients with sepsis die within two years
Half of all patients with sepsis admitted to an emergency medical department died within two years, according to researchers investigating factors that could predict outcomes for these patients.
-
NewsMosquitoes carrying Plasmodium and imported through parcels and luggage causing Odyssean malaria in Europe
Malaria cases resulting from bites of mosquitoes transported into Europe by aircraft from areas where it is common have increased, according to a number of studies.
-
NewsHospitals that are understaffed for infection prevention and control have higher rates of infection, study says
Inadequate infection prevention and control staffing levels are associated with higher rates of healthcare-associated infections, according to a new study published today in the American Journal of Infection Control. The study, conducted by the APIC Center for Research, Practice & Innovation, summarizes a pilot project to evaluate ...
-
NewsTrials show common cold medication significantly improved symptoms in less than two days
Applied Biological Laboratories will present results of a clinical trial which showed Biovanta significantly improved common cold symptoms including sore throat, cough, runny nose, congestion, chills, and sneezing in less than two days.
-
NewsFarewell to John Rigarlsford: a giant in biocides
Former AMI president Dr Peter Silley pays tribute to longstanding member and former committee representative John Rigarlsford, who recently passed away following a short illness.
-
NewsBiopolymers can be harnessed to develop sustainable antibacterial solutions
A new study presents a comprehensive analysis of how naturally abundant biopolymers can be harnessed to develop sustainable antibacterial solutions.
-
NewsScientists reveal how doxycycline for STI prevention affects the gut microbiome
Taking a dose of the oral antibiotic doxycycline after a high-risk sexual encounter has dramatically reduced the incidence of sexually transmitted infections (STIs) in places where the strategy is being tried. Source: NIAID Capsules of the antibiotic doxycycline Despite its effectiveness, the new strategy, known ...
-
NewsBovine H5N1 influenza may spread via milking
Milking practices may be linked to the transmission of bovine H5N1 influenza virus, which affects dairy cattle and was first detected in the U.S. in spring 2024.
-
NewsPromising TB therapy safe for patients with HIV
A therapy showing promise to help control tuberculosis (TB) does not interfere with combined antiretroviral therapy (cART), according to new research.
-
NewsGraphene spike mat and fridge magnet tech team up against antibiotic resistance
Researchers have deployed the bactericidal properties of graphene by using the same technology found in an ordinary fridge magnet, resulting in an ultra-thin acupuncture-like surface that can act as a coating on catheters and implants.
-
NewsCan a drug-free nasal spray protect against deadly respiratory infections?
A novel nasal spray for preventing respiratory infections works by forming a protective coating on the nasal cavity, which captures airborne respiratory droplets and acts as a physical barrier against viruses and bacteria, while effectively neutralizing them.
-
NewsEradivir closes $10.25M Series A funding round for next stage of influenza therapeutic trials
Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round which will be used to conduct a Phase 2a challenge study of its EV25 influenza treatment.
-
NewsResearchers investigate bunyaviruses and picornaviruses in bid to stave off next pandemic
A $13 million per year grant will enable researchers to accelerate their investigations of bunyaviruses, which include life-threatening respiratory and hemorrhagic fever viruses, and picornaviruses, notably enterovirus D68.
-
NewsResearchers identify critical immune factor for host defense against MRSA
Researchers identify a critical immune factor for host defense against MRSA, offering a potential explanation for failures of previous vaccine strategies and a proposal for a new direction for tackling this bacterium.
-
NewsResearchers to study how much MRSA is lurking in the air in hospitals
Scientists are working to minimize health care workers’ exposure to MRSA, or methicillin-resistant Staphylococcus aureus, a type of staph bacteria that’s become resistant to many of the antibiotics used to treat ordinary staph infections.
-
NewsMonoclonal antibodies offer hope for tackling antimicrobial resistance
Monoclonal antibodies – treatments developed by cloning a cell that makes an antibody – could help provide an answer to the growing problem of antimicrobial resistance, say scientists.
-
NewsWyss Institute selected to develop biologically engineered broad-spectrum antimicrobial therapeutic
The Wyss Institute for Biologically Inspired Engineering at Harvard University received a contract for up to $12M from the new SHIELD program which aims to develop a prophylactic treatment that can rapidly clear multiple bloodborne bacterial and fungal pathogens.
-
NewsSome guidelines for diagnosis and treatment of hepatitis E virus infection need a revamp, evaluation finds
A systematic evaluation of HEV infection guidelines revealed significant variability in their quality and recommendations. While some demonstrated strengths, others were found lacking in stakeholder involvement, rigor of development, and applicability.
-
NewsTriple antibody therapy shows promise for long-lasting HIV control
A cocktail of three broadly neutralizing antibodies (bNAb) successfully suppressed virus in people living with HIV, a new study shows. Some participants showed long-term control of the virus months after antibody levels declined to low or undetectable.